The US is unlikely to be able prevent another baby formula shortage like the one last year that left parents across the country searching desperately for supplies, a former Food and Drug Administration official told House lawmakers.
(Bloomberg) — The US is unlikely to be able prevent another baby formula shortage like the one last year that left parents across the country searching desperately for supplies, a former Food and Drug Administration official told House lawmakers.
“The necessary safeguards have not been advanced at an adequate pace to prevent future illnesses,” Frank Yiannas, former deputy commissioner of FDA’s Office of Food Policy & Response, said Tuesday in a House oversight hearing. “The infant formula supply chain continues to lack serious resilience.”
The industry has been under scrutiny since Abbott Laboratories, the biggest maker of infant formula for the US market, withdrew products including bestselling Similac last year after reports of illness and deaths among a few babies who had consumed it. The recall left parents across the country scrambling to find supplies and forced the US to expand its sources of the products.
Read More: How a Deadly Pathogen Spread at Abbott’s Infant Formula Plant
Yiannas stepped down from the FDA in February after an outside review found that its food division needed a stronger leader capable of ironing out interdepartmental conflicts crimping the agency’s ability to protect consumers.
In the hearing, lawmakers focused on areas where FDA oversight of the baby formula industry falls short. There is still no requirement for companies to report bacterial contamination found at manufacturing plants, Yiannas said.
“I think the abundance of evidence suggests that Abbott was operating under very unsanitary conditions and likely was sporadically contaminating infant formula,” Yiannas testified.
Abbott didn’t immediately respond to a request for comment. The Abbott Park, Illinois-based company has said there is no evidence to show its formulas caused the babies’ illnesses and deaths. The shares fell 0.6% at 11:26 a.m. in New York.
Earlier Tuesday, the agency proposed an “immediate” strategy to ensure safe, adequate supplies of baby formula. The FDA is working to inspect all infant formula manufacturers at least annually, increase training for inspectors and improve communication with formula makers, according to a report.
“We witnessed last year how a safety concern at one facility could be the catalyst for a nationwide shortage,” FDA Commissioner Robert Califf said in a statement before the hearing. “That’s why we are looking to both strengthen and diversify the market, while also ensuring that manufacturers are producing infant formula under the safest conditions possible.”
More stories like this are available on bloomberg.com
©2023 Bloomberg L.P.